Loading...
Market
Story
Pfizer's Lorbrena Shows 81% Reduction in Lung Cancer Progression in Five-Year Study
May 31, 2024, 02:12 PM
Pfizer's LORBRENA® CROWN study has demonstrated significant efficacy in treating a rare type of ALK-positive advanced lung cancer. The study shows that a majority of patients are living beyond five years without disease progression. The drug, Lorbrena, has reduced lung cancer progression by 81%, offering a substantial improvement in patient outcomes. This rare type of lung cancer is usually seen in nonsmokers. The study was highlighted by Pfizer $PFE and reported via @matthewherper at #ASCO24.
View original story
Similar markets
Less than 20% • 25%
20%-40% • 25%
40%-60% • 25%
More than 60% • 25%
None • 25%
1 • 25%
2 • 25%
3 or more • 25%
Less than 10% • 25%
10% to 25% • 25%
26% to 50% • 25%
More than 50% • 25%
0-10% • 25%
10-20% • 25%
20-30% • 25%
30%+ • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 20% • 33%
20% to 40% • 33%
Greater than 40% • 34%
Below 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
Above 75% • 25%
<10% • 25%
10%-25% • 25%
26%-50% • 25%
>50% • 25%
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
Amgen's Bkemv dominates • 33%
AstraZeneca retains majority market share • 33%
Other competitors gain significant market share • 34%